TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
2 citations
,
March 2016 in “Düşünen Adam” Switching from escitalopram to duloxetine improved hair loss.
138 citations
,
January 2004 in “AIDS” Some HIV treatments can harm mitochondria, potentially causing side effects like lactic acidosis and nerve damage.
1 citations
,
June 2022 in “JCRPE” Metreleptin treatment significantly improved metabolic health in a boy with congenital generalized lipodystrophy.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
102 citations
,
October 2010 in “Molecular Pharmaceutics” Copper-doxorubicin nanoparticles effectively treat tumors with less toxicity.
January 2023 in “Figshare” Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
149 citations
,
June 2002 in “Veterinary record/The veterinary record” Trilostane effectively improved symptoms in dogs with a certain adrenal gland disorder.
13 citations
,
July 2010 in “Drug safety” Lamotrigine may cause hair loss, affecting treatment compliance and health.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
7 citations
,
January 2022 in “Bioengineering” The formulation with oleic acid may be better for treating male pattern baldness.
10 citations
,
October 2016 in “Epilepsy & behavior” Levetiracetam often causes behavioral issues, while oxcarbazepine is more likely to cause sleepiness in epilepsy patients.
Baricitinib works better than methotrexate for severe alopecia areata.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
52 citations
,
January 2005 in “PubMed” Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.
9 citations
,
February 2022 in “European Journal of Pharmaceutics and Biopharmaceutics” A new treatment for hair loss uses tiny lipid carriers to deliver a mix of minoxidil and latanoprost directly to hair follicles, promoting hair growth and being well tolerated by the skin.
32 citations
,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
22 citations
,
May 2003 in “Planta Medica” Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.
Optimized liposomes can improve drug delivery and effectiveness.
9 citations
,
February 1996 in “Lancet” Some tuberculosis drugs may cause hair loss, but hair might regrow after treatment or changing the drugs.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
February 2010 in “Journal of The American Academy of Dermatology” Posaconazole is a promising new treatment for toenail fungus.
24 citations
,
October 2008 in “International Braz J Urol” Lovastatin doesn't improve lower urinary tract symptoms treatment.
41 citations
,
November 1987 in “British Journal of Dermatology” Ketoconazole cured about 70% of cutaneous leishmaniasis cases caused by Leishmania major.
68 citations
,
April 2012 in “Digestive and Liver Disease” Elental is a good long-term treatment for Crohn's disease, similar to 6-mercaptopurine but with fewer side effects.
January 2023 in “Zenodo (CERN European Organization for Nuclear Research)” A new accurate and reliable method was developed to measure Spironolactone and Hydrochlorothiazide together in medicines.